Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
about
The PCSK9 decadeFrom proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsPCSK9 and triglyceride-rich lipoprotein metabolismPCSK9 and Atherosclerosis - Lipids and Beyond.New frontiers in the treatment of diabetic dyslipidemiaProprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.Birth Cohort, Age, and Sex Strongly Modulate Effects of Lipid Risk Alleles Identified in Genome-Wide Association Studies.Decreased PCSK9 expression in human hepatocellular carcinoma.Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal BloodPlasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery diseaseDyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.Do persons with diabetes benefit from combination statin and fibrate therapy?New lipid-lowering drugs: an update.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Calorically restricted diets decrease PCSK9 in overweight adolescents.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes.Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.PCSK9 and carbohydrate metabolism: A double-edged sword.Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers.Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
P2860
Q24615397-2D086C95-8FB9-45DF-8487-EEA7A37D858AQ26741078-A1C85E37-BB78-4BB3-9876-74FD4BC0DFB2Q26796287-0D15D91B-7057-485E-9FCF-69E7D2C46F36Q33675963-2C70E3A9-0B21-43DE-A61D-8543B6CDE105Q33776236-24AB858C-C2F0-46D3-B2FC-697C7E1F0783Q33970677-83397CF5-6230-40F9-B4FF-3334BD873220Q34321484-BEFED51A-FA09-4CB0-99BE-C6F65CE2918CQ34458693-0BA1B2D3-9040-4B30-8260-DA9E7F7922D0Q34536594-3ACFDA25-B10A-4232-8328-639F88CE461AQ34937512-CC1E06B1-4AFF-44C8-B3FE-07D4317A978BQ35752147-2F7855FA-438E-4D47-B0DD-BC49AF283736Q35870767-E7AD001D-76C3-4AC7-B9D9-7E9B7196F9FEQ35897064-9BBB6D82-56DA-4633-8815-700F50A6F353Q36035643-D5E279A4-E2D4-4570-BDBD-578DA8BEAFEEQ36529674-C327BA58-01FA-4F4A-A0CB-32405B15AAE2Q36574008-35E65E1C-B306-43E3-B692-4F37E00DF1B6Q36602940-52D9944C-C033-44B3-8049-74D23DD94029Q36942743-FB2F67E6-B55A-4BD4-8B22-A81028AD04CAQ36956822-FBF8A62F-C466-49DA-BBD2-27BE126D3380Q37173897-FAD2ACA6-C95B-4164-A30B-E802E2433F99Q37278608-E49AD5BD-9969-4317-B104-9CDD32F1C7B4Q37466735-876A6931-115F-404C-8CFF-C3581B173621Q37972824-CEC1A374-A666-473E-9937-4FDA888D61C6Q37984782-FD76A04B-9644-4E0A-91B9-C97888BCDE1AQ38001736-ADD8544D-98F1-4924-BD7E-A0AE7CB4003CQ38067634-97FBFEE6-602F-4C39-B6CE-9BB896F57300Q38095872-E06E63F0-00C0-43D5-B1A3-9AE2BF7D0DC5Q38153456-1B180DF1-0946-4DC0-9BDF-BA8E2EFEA08CQ38221015-F30645AB-9B95-4229-8415-B141B8C1ECEEQ38380440-9BE6B798-2276-46B8-95CD-A030B388CEAEQ38637552-3B62680F-FA47-44E1-9374-A45841E43ED8Q38796312-7A7369D4-D42D-4046-9D70-96B948CF5703Q39017494-5849501E-9591-44FC-B36E-69B5F295FE11Q40532465-1BBB0233-8F49-45B3-B8B5-794B11F3EB4BQ40899815-F5712C9C-4340-4A53-856A-A4F9544A8288Q42333207-7AD43855-15B9-4299-BE2B-382AFEF3AB78Q42869880-A9600E49-0D84-4065-9D2E-AA878E9E2FEEQ46414850-7F0AE0B3-3A4E-4F7F-AD25-E68F772CBFF9Q47101735-D3804BBD-960A-41F0-871A-58CCFD2801C5Q47567094-94C7EE34-59EB-4B16-A12E-4DACA1BAC919
P2860
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@ast
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@en
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@nl
type
label
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@ast
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@en
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@nl
prefLabel
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@ast
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@en
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@nl
P2093
P1433
P1476
Plasma PCSK9 is associated wit ...... e of children and adolescents.
@en
P2093
Alexis Baass
Edgard E Delvin
Emile Levy
Geneviève Dubuc
Jean Davignon
Jennifer O'Loughlin
Marie Lambert
Michel Tremblay
P304
P356
10.1373/CLINCHEM.2009.126987
P407
P577
2009-07-23T00:00:00Z